Colgate To Develop Anti-Cancer Toothpastes And Mouthwashes
... a wide range of molecular therapeutics that include tumor suppressors such as p53, mda-7, and FUS1. The company is in an advanced stage of developing ingn
234, a mouthwash designed to deliver the p53 tumor suppressor for the prevention of a pre-cancerous condition called Leukoplakia as well as oral cance...
Preclinical Studies Identify Novel Approach for Enhancing the
Anticancer Activity of Introgen's INGN 241
AUSTIN, Texas--(BUSINESS WIRE)--Apr 25, 2007 - Introgen
Therapeutics, Inc. (NASDAQ:INGN) today announced the publication of
new preclinical data describing how an intrinsic cell survival
pathway impacts the anticancer activity of INGN
241. Inhibition of
this pathway, known as NF-kB, enhanced the tu...
Introgen Reports Promising Phase 1/2 Clinical Results With INGN 241
in Patients With Advanced Solid Tumors
SEATTLE--(BUSINESS WIRE)--Jun 1, 2007 - Introgen Therapeutics, Inc.
(NASDAQ:INGN) reported promising Phase 1/2 clinical data with INGN
241, the Company's novel investigational mda-7/IL-24 tumor
suppressor agent, in patients with advanced solid tumors.
The data (Abstract #380), which were presented...
Introgen Presents ADVEXIN Biomarker Data at Major Cancer Conference
...sented regarding Introgen's
other Phase 3 product, ingn
241, indicating that inhibitors of a
class of stre...eath. These pre-clinical data provide
insight into ingn
241 mechanisms of action and identify future
strat...and 3 clinical trials conducted worldwide.
Introgen and Clinical Collaborators to Report New Results with
Advanced-Stage Cancer Therapies at Upcoming Medical Meetings
...ts, including those relating to
Introgen's future success with its ADVEXIN, ingn
241, and ingn
clinical development programs. The actual results may differ from